RPG Life Sciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.75×	0.75×	—	—	—
	1.12×	1.23×	—	—	—
	17.3%	17.8%	—	—	—
	0.98×	0.98×	—	—	—
	1.29×	1.31×	1.24×	1.37×	1.36×
	18.3%	20.9%	—	—	—
	20.3%	20.3%	—	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

RPGLIFE₹2,844.00

RPG Life Sciences Limited

· Pharma & Health

₹ CrorePeersGUFICBIO GUJTHEM UNICHEMLAB ORCHPHARMA SMSPHARMA FDC IOLCP INDSWFTLABMcap ₹4,703 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	—	—	—	0.75	0.75
Interest Burden (Pretax/EBIT) ×	—	—	—	1.23	1.12
EBIT Margin %	—	—	—	17.75	17.33
Asset Turnover ×	—	—	—	0.98	0.98
Financial Leverage (Assets/Equity) ×	1.36	1.37	1.24	1.31	1.29
ROE (5-step product, year-end total equity) %	—	—	—	20.90	18.34
ROE (owners' profit / average owners' equity) %	—	—	—	20.28	20.28

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.